Today, the listing ceremony of Guangzhou LBP Medicine Science & Technology Co., Ltd. (stock abbreviation: LBP, stock code: 688393) on the Science and Technology Innovation Board was held simultaneously at Shanghai Stock Exchange and the South Center of Shanghai Stock Exchange (Guangzhou), which is the first stock in the field of domestic pathology diagnosis and an important moment in the history of LBP. Mr. Cai Xiangting, Chairman and General Manager of LBP, Mr. Zhang Hui, Deputy Director of the Management Committee of Guangzhou Development Zone, Mr. Tang Keming, Deputy Director General of the Financial Work Bureau of Guangzhou Development Zone, Mr. Yang Weidong, Executive Vice President and President of Investment Banking Division of Minsheng Securities Co., Ltd., Mr. Wang Youming, Director, Secretary of the Board of Directors and Deputy General Manager of LBP, Mr. Chen Wuke, Director of LBP, Ms. Huang Qing, Representative of Shareholders, Chairman of Shenzhen Gaotejia Hongrui Investment Co., Ltd., and Mr. Zhou Xinyu, Director and General Manager of DAAN Gene Co., Ltd. Of Sun Yat-sen University and other shareholders and representatives of intermediary teams, as well as LBP's top management team, attended this listing ceremony at Shanghai Stock Exchange to witness this milestone moment together.
Mr. Cai Xiangting, Chairman and General Manager of LBP, delivered a speech. Firstly, he thanked the government leaders at all levels, customers, employees and related organizations who have been caring and supporting LBP. Since its establishment, LBP has been focusing on its main business and working intensively to have its products covered the three major technology platforms of pathological diagnosis, and now it has become one of the manufacturers with the most complete product lines and the most diversified products in the field of pathological diagnosis in China. With this successful listing, LBP will continue to increase its investment in R&D, abide by quality first, continuously improve its comprehensive strength, and contribute to the development of China's in vitro diagnostic industry. In the meantime, LBP will also comply with relevant laws and regulations, strictly fulfill the relevant provisions, and safeguard the legitimate rights and interests of investors.
Mr. Zhang Hui, Deputy Director of the Management Committee of Guangzhou Development Zone, and Mr. Yang Weidong, Executive Vice President and President of Investment Banking Division of Minsheng Securities Co., Ltd. both expressed their warm congratulations and good expectations for LBP's listing in their subsequent speeches, hoping that LBP would seize the opportunity of access to the capital market, continuously strengthen its core competitiveness, consolidate and enhance its position in the industry, and contribute to the development of private enterprises in Guangzhou and the capitalization of Chinese enterprises.
The simultaneous listing ceremony at Guangzhou branch was also the first time for SSE South Center to try to hold a simultaneous listing ceremony in two places. Mr. Xu Xiubin, Deputy Director General of Guangzhou Local Financial Administration, Ms. Wu Guan, Principal Officer I of Capital Market Division of Guangzhou Bureau of Finance, Ms. He Yingyue, Investigator IV of the Finance Bureau of Guangzhou Development Zone, Mr. Cen Youhui, Section Chief of the Finance Bureau of Guangzhou Development Zone, Mr. Chen Guanghui, Deputy Director General of the Intellectual Property Office of Guangzhou Development Zone, Mr. Ding Bodong, Deputy Secretary General of the Listed Companies Association of Guangdong, and other guests and LBP's staff representatives attended the listing ceremony at Guangzhou Branch, and witnessed the historical moment of LBP's listing on the SSE STAR Market.
LBP profile
Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and listed on the SSE STAR Market on August 20, 2020 (stock code: 688393, stock abbreviation: LBP), which is the first listed company in the field of pathological diagnosis in China. The Company is headquartered in the Science City and has a new industrial park of nearly 30,000㎡, mainly engaged in the R&D, production, sales and service of in vitro diagnostic reagents and instruments. Since its establishment, the Company has been focusing on its main business and working intensively, has built a diversified technology platform, and has independently developed a number of core technologies such as sedimentation liquid-based cytology technology, reverse dot blot PCR preparation technology, real-time fluorescent PCR preparation technology, FISH probe labeling technology, IHC pathological diagnostic antibody screening and quality control technology and related supporting instrument manufacturing technologies. The Company is one of the manufacturers with the most complete product lines and the most diversified products in the field of pathological diagnosis in China, and can meet the needs of medical institutions at different levels. Both the Company and its subsidiary Guangzhou LBP Automatic Testing Equipment Co. Ltd. have obtained the national high-tech enterprise certificate, have been awarded the title of "high-tech Products of Guangdong Province" for 16 core products, and have also obtained a number of honors such as Guangdong Innovative Enterprise (Pilot) in 2018, Guangdong Research Center of Pathological Diagnosis Engineering Technology, etc. The products have passed EU CE certification, and quality certification by British Standards Institute (BSI) and Japan Ministry of Health, Labour and Welfare. Over the years, the Company has participated in a number of national major projects under the "863 Program", provincial and municipal projects, obtained 61 authorized patents, including 15 invention patents, and formed 29 related software copyrights, and has more than 500 registered/recorded products, the number of which is continuously increasing. With the synergistic advantages of our own brand reagents and instruments, perfect marketing network and high-quality service system, our products have covered nearly 1,800 medical institutions nationwide.
The Company has always adhered to the corporate purpose of "creating value for society and customers to achieve employee and corporate value", and has been focusing on the business development of in vitro diagnostics, especially pathological diagnostic products related to tumor diseases. The Company gives great impetus to R&D innovation and industrialization of technological achievements, strengthens the construction of multi-level marketing network, builds an innovative business mode of online and offline integrated in vitro diagnostic ecosystem, and accelerates the cultivation of the in vitro diagnostic market, to continuously enhance the Company's brand influence. The Company is committed to becoming a leading domestic in vitro diagnostic company integrating R&D, production, sales, service and education and training of pathological diagnosis technologies.
